Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 76.25
+0.10 (0.13%)
Sep 16, 2026, 5:35 PM CET
Pharma Mar Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,320 | 1,289 | 1,389 | 738 | 1,158 | 1,033 | |
Market Cap Growth | -14.86% | -7.20% | 88.09% | -36.23% | 12.13% | -21.36% |
Enterprise Value | 1,197 | 1,193 | 1,298 | 608 | 1,014 | 866 |
Last Close Price | 76.15 | 74.00 | 78.06 | 39.50 | 60.94 | 53.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.47 | 17.19 | 53.17 | 649.51 | 23.46 | 11.12 |
Forward PE | 18.07 | 24.03 | 36.29 | 67.76 | 16.74 | 12.76 |
PS Ratio | 6.04 | 5.82 | 7.94 | 4.67 | 5.90 | 4.49 |
PB Ratio | 5.26 | 5.12 | 6.67 | 3.82 | 5.19 | 5.81 |
P/TBV Ratio | 5.35 | 5.15 | 6.70 | 3.84 | 5.22 | 5.84 |
P/FCF Ratio | 24.44 | 27.62 | - | - | 39.30 | 57.78 |
P/OCF Ratio | 21.22 | 24.26 | 230.47 | - | 30.22 | 40.22 |
PEG Ratio | 0.86 | 0.09 | 0.33 | 2.22 | 26.93 | 5.37 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.48 | 5.39 | 7.42 | 3.84 | 5.17 | 3.77 |
EV/EBITDA Ratio | 25.61 | 17.94 | 128.91 | - | 22.60 | 9.12 |
EV/EBIT Ratio | 30.80 | 19.64 | 200.70 | - | 24.11 | 9.37 |
EV/FCF Ratio | 22.16 | 25.56 | - | - | 34.42 | 48.46 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.18 | 0.20 | 0.25 | 0.23 | 0.19 | 0.28 |
Debt / EBITDA Ratio | 0.98 | 0.72 | 4.19 | 48.68 | 0.91 | 0.51 |
Debt / FCF Ratio | 0.85 | 1.06 | - | - | 1.45 | 2.76 |
Net Debt / Equity Ratio | -0.49 | -0.47 | -0.50 | -0.61 | -0.63 | -0.86 |
Net Debt / EBITDA Ratio | -2.74 | -1.77 | -10.27 | 103.75 | -3.11 | -1.61 |
Net Debt / FCF Ratio | -2.28 | -2.52 | 11.51 | 4.21 | -4.74 | -8.53 |
Asset Turnover | 0.59 | 0.60 | 0.51 | 0.43 | 0.52 | 0.66 |
Inventory Turnover | 0.29 | 0.24 | 0.18 | 0.29 | 0.71 | 1.46 |
Quick Ratio | 2.20 | 2.20 | 2.29 | 1.98 | 2.18 | 2.93 |
Current Ratio | 2.86 | 3.02 | 3.03 | 2.63 | 2.83 | 3.42 |
Return on Equity (ROE) | 24.82% | 32.59% | 13.00% | 0.55% | 24.62% | 66.18% |
Return on Assets (ROA) | 6.55% | 10.19% | 1.17% | -0.65% | 6.91% | 16.54% |
Return on Invested Capital (ROIC) | 30.23% | 50.82% | 7.21% | -4.85% | 77.52% | - |
Return on Capital Employed (ROCE) | 13.20% | 20.20% | 2.40% | -1.60% | 14.20% | 32.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.25% | 5.82% | 1.88% | 0.15% | 4.26% | 8.99% |
FCF Yield | 4.09% | 3.62% | -0.65% | -3.83% | 2.54% | 1.73% |
Dividend Yield | 1.20% | 1.35% | 1.03% | 1.65% | 1.07% | 1.21% |
Payout Ratio | - | 18.60% | 43.71% | 1028.06% | 23.83% | 11.71% |
Buyback Yield / Dilution | -3.57% | 0.62% | 1.98% | 0.81% | 0.12% | 1.31% |
Total Shareholder Return | -2.38% | 1.97% | 3.00% | 2.46% | 1.19% | 2.52% |